


Scifinder

B303098079 陳彥欽

題目：TAXOL



先進入搜尋畫面然後打上 Taxol 我在下面點選了 clinical trail, Journal 在語言列選擇了中文和英文，開始搜尋找到了很多篇挑出下面一篇，本來想找出全文但是好像權限不足。

The screenshot shows the SciFinder web interface in a Windows Internet Explorer browser. The main content area displays the title "8. Taxol-induced alteration of intracellular amino-acid profile related to human cervical carcinoma HeLa cell death" by Han, Xiao-Fei; Liu, Yan-Qiu; Wang, Long-Xing; Yang, Qian-Xu; Xiao, Hong-Bin. The abstract describes the anti-tumor action of Taxol and its effect on intracellular amino-acid profiles of HeLa cells. The right sidebar contains quick links, source information (Biotechnology Letters, Volume 34, Issue 1, Pages 1-7), company/organization (Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics), accession number (2011:1598596), and publisher (Springer). The bottom of the browser shows the Windows taskbar with the time 1:59 PM.

8. Taxol-induced alteration of intracellular amino-acid profile related to human cervical carcinoma HeLa cell death

By: Han, Xiao-Fei; Liu, Yan-Qiu; Wang, Long-Xing; Yang, Qian-Xu; Xiao, Hong-Bin

The anti-tumor action of Taxol was investigated in the changes of amino-acids involved in tumor cell survival. By tracing the intracellular amino-acid profiles of HeLa cells treated with non-conditioned and three conditioned media (Taxol, l-alanine, and Taxol + l-alanine), it was obsd. that an alteration of amino-acid metab. participates in Taxol-induced death of HeLa cells. The contents of 18 out of 21 detected amino-acids are 5-95% and the ones of lysine and methionine are 158 and 117% of the corresponding contents in the control after treatment with Taxol for 24 h, resp. Addn. of l-alanine inhibited cell apoptosis upon Taxol treatment by partially blocking the increase of lysine and methionine and reversing decrease trend of alanine, glycine, and glutamic acid. These results suggest that interference of amino-acid metab. might be an important mechanism of Taxol cytotoxicity.

使用心得：使用 Scifinder 檢索可以快速的找到目前最新的研究報告和期刊論文，也可以依個人需要點選不同的分類例如臨床上的用法、化學結構、出版年份等等，所以學會 Scifinder 的使用對於研究上來說非常重要，是保持不和世界脫軌的最佳軟體。

Thomson Innovation

進入系統後搜尋 opioids

找到這篇專利

The screenshot shows a web browser window titled "Thomson Innovation - Windows Internet Explorer". The address bar displays the URL: <http://www.thomsoninnovation.com/ip-innovation/recordView.do?pager.offset=9&recordCount=10&parentId=null&totalRecords=149&fromRecordView=false&dataSource=T3&category=PAT&selRecord=>. The page title is "Patent Record View - US7399488B2". The main content area is titled "Record View: Patent US7399488B2" and includes a "Quick View" section on the left and an "Images" section on the right. The "Quick View" section contains the following information:

- DWPI Title ?**
Orally administrable pharmaceutical composition for preventing drug abuse through controlled release comprises lipophilic derivative of a drug prone to abuse
- Original Title ?**
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
- Abstract ?**
An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

The "Images" section on the right displays a thumbnail image of the patent document. The bottom of the page shows a Windows taskbar with various open applications and the system clock.

DWPI Title

?

Orally administrable pharmaceutical composition for preventing drug abuse through controlled release comprises lipophilic derivative of a drug prone to abuse

Original Title

?

Abuse-deterrent pharmaceutical compositions of opioids and other drugs

Abstract

?

An abuse-deterrent pharmaceutical composition has been developed to reduce the

likelihood of improper administration of drugs, especially drugs such as opioids. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

First Claim

?

1. An orally administrable abuse-deterrent pharmaceutical composition comprising a therapeutically effective amount of microparticles consisting of
 - (a) a lipophilic drug prone to abuse or lipophilic derivative of a drug prone to abuse, and
 - (b) one or more carrier materials selected from the group consisting of fats, fatty substances, waxes, wax-like substances and mixtures thereof,
 - wherein the drug is dispersed within the one or more carrier materials, and the release of a portion of incorporated drug is retarded when the physical integrity of the composition is compromised and the compromised composition is exposed to water.

使用這個軟體可以找到目前藥物開發上很多的專利，例如這篇是講鴉片類藥物的投與方式的專利，裡面可以看到大略的專利內容專利日期所有權等等，在開發藥物的過程中這個軟體可以避免踩到別人的專利，也可以避免浪費太多時間研究到最後發現早已被人專利註冊過了窘境，如果功能更齊全的話可以找到更多的相關資料，對於研究上有很大的幫助。